Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.
Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. Lau G, et al. Among authors: mok t. Hepatol Int. 2021 Oct;15(5):1031-1048. doi: 10.1007/s12072-021-10239-x. Epub 2021 Aug 24. Hepatol Int. 2021. PMID: 34427860 Free PMC article.
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.
Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tanwandee T, Sarin SK, Omata M. Lau G, et al. Among authors: mok t. Hepatol Int. 2022 Apr;16(2):486-487. doi: 10.1007/s12072-022-10301-2. Epub 2022 Jan 25. Hepatol Int. 2022. PMID: 35076895 Free PMC article. No abstract available.
Being molecular in the molecular age.
Raghupathy R, Mok T. Raghupathy R, et al. Among authors: mok t. Ann Oncol. 2016 Mar;27(3):367-8. doi: 10.1093/annonc/mdw002. Ann Oncol. 2016. PMID: 26924595 Free article. No abstract available.
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.
Li MSC, Lee KWC, Mok KKS, Loong HHF, Lam KC, Mok FST, Chan LL, Lau YM, Chan KP, Ng JTY, Wong WKY, Lam BHW, Chen ACC, Lee MMP, Chen OH, Mok TSK. Li MSC, et al. Among authors: mok tsk. JTO Clin Res Rep. 2024 Feb 10;5(4):100648. doi: 10.1016/j.jtocrr.2024.100648. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38590729 Free PMC article.
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML. Garon EB, et al. Among authors: mok ts. Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00038-X. doi: 10.1016/j.cllc.2024.03.003. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38584069 Free article. No abstract available.
A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.
Zheng X, Lu T, Wu S, Lin X, Bai J, Chen X, Miao Q, Yan J, Jiang K, Zhang L, Zheng X, Wang H, Xu Y, Xiao W, Li C, Peng W, Ding J, Zhong Q, Zou Z, Yang S, Li Y, Chen S, Zhang Q, Yan J, Tang G, Cai Y, Kang M, Mok TSK, Lin G. Zheng X, et al. Among authors: mok tsk. MedComm (2020). 2024 Mar 9;5(3):e493. doi: 10.1002/mco2.493. eCollection 2024 Mar. MedComm (2020). 2024. PMID: 38463396 Free PMC article.
588 results